Second-line treatment for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs—nab-paclitaxel (a chemotherapy drug) and cadonilimab (an immunotherapy drug)—for people with advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this combination can help shrink or control the cancer when other treatments haven't been tried yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen (peritoneal metastasis).
- You have not received any prior treatment for your cancer.
- You are willing to provide blood and tissue samples for research.
- You are generally healthy enough to carry out daily activities (ECOG score 0 or 1).
- Your liver, kidney, and blood function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new chemotherapy combination for patients with advanced stomach cancer that has worsened after initial treatment. It aims to find a better second-line option using a drug called nab-paclitaxel.
This trial tests a combination of three drugs (adebrelimab, apatinib, and paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has progressed after immunotherapy. The goal is to see if this combination helps control the cancer longer.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
This trial tests a new immunotherapy drug called cadonilimab combined with chemotherapy before surgery for stomach or gastroesophageal junction cancer. The goal is to shrink the tumor and improve outcomes for patients who are candidates for surgery.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.